Coto C, Varela G, Hernández V, del Rosario M, López-Saura P
Pedro Borrás Paediatric Hospital, Havana, Cuba.
Biotherapy. 1998;11(1):15-20. doi: 10.1023/a:1007932130188.
Recombinant interferon (IFN) gamma was used in 10 patients, 6 to 15 years old, with juvenile chronic arthritis (JCA) for 5 to 11 years, resistant or with severe side effects to other treatments. Six patients had systemic JCA and 4 started as pauciarticular. Three of the latter became polyarticular. Treatment schedule was 50,000 IU-kg daily for 4 weeks, then 3 times per week for 3 months and twice a week up to 2 years. Eight cases had favourable clinical response. Prolonged steroid regime could be suspended in 7/8 cases who previously received it. Two patients with systemic JCA did not respond to IFN treatment. Side effects were fever (9), headache (8), chills (6), distal cyanosis, hypotension, leukopenia and myalgia (2), and vomiting (1). All were mild or moderate. IFN gamma was more tolerable than other drugs and seems to be beneficial for patients with JCA resistant to other treatments.
重组干扰素γ被用于10例6至15岁患青少年慢性关节炎（JCA）5至11年、对其他治疗耐药或出现严重副作用的患者。6例为全身型JCA，4例最初为少关节型。后者中有3例发展为多关节型。治疗方案为每日50,000 IU/kg，持续4周，然后每周3次，持续3个月，之后每周2次，持续2年。8例有良好的临床反应。在之前接受过长期类固醇治疗的8例患者中，7例可以停用类固醇。2例全身型JCA患者对干扰素治疗无反应。副作用包括发热（9例）、头痛（8例）、寒战（6例）、远端发绀、低血压、白细胞减少和肌痛（2例）以及呕吐（1例）。所有副作用均为轻度或中度。干扰素γ比其他药物更易于耐受，似乎对耐其他治疗的JCA患者有益。
